Which pharmaceutical companies have the most gel dosed drugs?

This chart shows the pharmaceutical companies with the most gel dosed drugs.

For a different perspective, see the most popular dosage types.

The companies with the most gel dosed drugs are:

For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs,
contact admin@DrugPatentWatch.com
or visit www.DrugPatentWatch.com

New patent for Novo Nordisk drug SAXENDA

Annual Drug Patent Expirations for SAXENDA
Annual Drug Patent Expirations for SAXENDA

Saxenda is a drug marketed by Novo Nordisk Inc
and is included in one NDA. It is available from one supplier. There are fourteen patents protecting this drug.

This drug has two hundred and one patent family members in twenty-four countries.

The generic ingredient in SAXENDA is liraglutide recombinant. One supplier is listed for this compound. Additional details are available on the liraglutide recombinant profile page.

For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs,
contact admin@DrugPatentWatch.com
or visit www.DrugPatentWatch.com

New patent for Novo Nordisk drug RYZODEG 70/30

Annual Drug Patent Expirations for RYZODEG+70%2F30
Annual Drug Patent Expirations for RYZODEG+70%2F30

Ryzodeg 70/30 is a drug marketed by Novo Nordisk Inc
and is included in one NDA. There are eleven patents protecting this drug.

This drug has one hundred and forty-six patent family members in twenty-four countries.

The generic ingredient in RYZODEG 70/30 is insulin aspart; insulin degludec. Additional details are available on the insulin aspart; insulin degludec profile page.

For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs,
contact admin@DrugPatentWatch.com
or visit www.DrugPatentWatch.com

Which pharmaceutical companies have the most SPCs in Sweden?

This chart shows the pharmaceutical companies with the most supplementary protection certificates (SPCs) in Sweden.

SPCs are used in European Union and select others to encourage pharmaceutical innovation by
compensating for the long time needed to obtain regulatory approval for drugs. SPCs
come into force only after the corresponding general patent expires, and normally have a maximum lifetime of 5 years.

The total combined duration of market exclusivity of a general patent and SPC cannot normally exceed 15 years, but a six-month extention
may be obtained by responding to a request for pediatric trials.

For a different perspective, see the drug companies with SPCs in the most countries

The pharma companies with the most SPCs in Sweden are:

For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs,
contact admin@DrugPatentWatch.com
or visit www.DrugPatentWatch.com

New patent for Iroko Pharms drug VIVLODEX

Annual Drug Patent Expirations for VIVLODEX
Annual Drug Patent Expirations for VIVLODEX

Vivlodex is a drug marketed by Iroko Pharms Llc
and is included in one NDA. It is available from one supplier. There is one patent protecting this drug.

This drug has eight patent family members in eight countries.

The generic ingredient in VIVLODEX is meloxicam. One supplier is listed for this compound. Additional details are available on the meloxicam profile page.

For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs,
contact admin@DrugPatentWatch.com
or visit www.DrugPatentWatch.com

New patent for Cerexa drug TEFLARO

Annual Drug Patent Expirations for TEFLARO
Annual Drug Patent Expirations for TEFLARO

Teflaro is a drug marketed by Cerexa
and is included in one NDA. It is available from one supplier. There are four patents protecting this drug and one Paragraph IV challenge.

This drug has thirty-seven patent family members in sixteen countries.

The generic ingredient in TEFLARO is ceftaroline fosamil. One supplier is listed for this compound. Additional details are available on the ceftaroline fosamil profile page.

For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs,
contact admin@DrugPatentWatch.com
or visit www.DrugPatentWatch.com

New patent for Novo Nordisk drug LEVEMIR PENFILL

Annual Drug Patent Expirations for LEVEMIR+PENFILL
Annual Drug Patent Expirations for LEVEMIR+PENFILL

Levemir Penfill is a drug marketed by Novo Nordisk Inc
and is included in one NDA. It is available from four suppliers. There are two patents protecting this drug.

This drug has seventy-three patent family members in twenty-eight countries.

The generic ingredient in LEVEMIR PENFILL is insulin detemir recombinant. Four suppliers are listed for this compound. Additional details are available on the insulin detemir recombinant profile page.

For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs,
contact admin@DrugPatentWatch.com
or visit www.DrugPatentWatch.com

New patent for Novo Nordisk drug LEVEMIR INNOLET

Annual Drug Patent Expirations for LEVEMIR+INNOLET
Annual Drug Patent Expirations for LEVEMIR+INNOLET

Levemir Innolet is a drug marketed by Novo Nordisk Inc
and is included in one NDA. It is available from four suppliers. There are two patents protecting this drug.

This drug has seventy-three patent family members in twenty-eight countries.

The generic ingredient in LEVEMIR INNOLET is insulin detemir recombinant. Four suppliers are listed for this compound. Additional details are available on the insulin detemir recombinant profile page.

For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs,
contact admin@DrugPatentWatch.com
or visit www.DrugPatentWatch.com

New patent for Novo Nordisk drug LEVEMIR FLEXTOUCH

Annual Drug Patent Expirations for LEVEMIR+FLEXTOUCH
Annual Drug Patent Expirations for LEVEMIR+FLEXTOUCH

Levemir Flextouch is a drug marketed by Novo Nordisk Inc
and is included in one NDA. It is available from four suppliers. There are eleven patents protecting this drug.

This drug has one hundred and fifty-nine patent family members in twenty-eight countries.

The generic ingredient in LEVEMIR FLEXTOUCH is insulin detemir recombinant. Four suppliers are listed for this compound. Additional details are available on the insulin detemir recombinant profile page.

For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs,
contact admin@DrugPatentWatch.com
or visit www.DrugPatentWatch.com